MedTrace Logo

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

NCT02584634 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2023-07-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.

Conditions

Interventions

DRUG

Avelumab

Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg

DRUG

PF-06463922

Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.

DRUG

Crizotinib

Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-18
Primary Completion
2021-02-02
Completion
2022-07-13
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Japan
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584634 on ClinicalTrials.gov